- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.10. | 20/20 Biolabs Inc.: 20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026 | 1 | GlobeNewswire (USA) | ||
| 20/20 BIOLABS Aktie jetzt für 0€ handeln | |||||
| 02.09. | 20/20 Biolabs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | 20/20 BioLabs Cancer-Test Revenue Jumps 47% As Firefighter Screening Programs Expand | 1 | pulse2.com | ||
| 17.08. | 20/20 Biolabs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.08. | 20/20 Biolabs Q2 GAAP EPS of -$0.26, revenue of $0.73M | 1 | Seeking Alpha | ||
| 17.08. | 20/20 Biolabs Inc.: 20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level | 256 | GlobeNewswire (Europe) | Best Quarter of Flagship Multi-Cancer Early Detection Testing; OneTest Revenue Increased 47% Year-Over-Year to $0.7 Million; Gross Profit Increased 87% to $0.3 Million, with Gross Margin Expanding... ► Artikel lesen | |
| 05.08. | 20/20 Biolabs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.07. | 20/20 BioLabs meets potential partners in East Asia | 1 | Investing.com | ||
| 27.07. | 20/20 Biolabs Inc.: 20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy | 1 | GlobeNewswire (USA) | ||
| 23.07. | 20/20 Biolabs Inc.: 20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock | 208 | GlobeNewswire (Europe) | Agreement Temporarily Restricts Preferred-to-Common Stock Conversions Below a Defined Price Threshold, Mitigating Potential Near-Term Dilution GAITHERSBURG, Md., July 23, 2026 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| 22.07. | 20/20 Biolabs, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.07. | 20/20 BioLabs reports Q2 MCED revenue to be highest to date | 1 | Investing.com | ||
| 01.07. | 20/20 Biolabs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | 20/20 Biolabs Inc.: 20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters | 3 | GlobeNewswire (USA) | ||
| 22.05. | 20/20 Biolabs: Pläne für Ebola-Tests treiben Aktie an | 1 | Investing.com Deutsch | ||
| 22.05. | 20/20 Biolabs Inc.: 20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand | 2 | GlobeNewswire (USA) | ||
| 20.05. | 20/20 Biolabs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 20.05. | 20/20 Biolabs, Inc. GAAP EPS of -$0.28 misses by $0.18, revenue of $0.35M misses by $0.43M | 1 | Seeking Alpha | ||
| 20.05. | 20/20 Biolabs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | 20/20 Biolabs Inc.: 20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 46,100 | +1,75 % | JPMORGAN stuft Fresenius SE auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - JPMorgan hat Fresenius nach Gesprächen mit der Investor-Relations-Abteilung mit einem Kursziel von 55,20 Euro auf "Overweight" belassen. Die Aktien stehen zudem auf der... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 60,11 | 0,00 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 41,860 | +0,24 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,460 | +3,27 % | JPMORGAN stuft FMC FRESENIUS MEDICAL CARE AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat FMC nach Gesprächen mit dem Unternehmen mit einem Kursziel von 32,30 Euro auf "Underweight" belassen. Die Quartalszahlen des Dialysespezialisten... ► Artikel lesen | |
| GENEDX | 56,08 | -0,12 % | GeneDx plans to add long-read genome sequencing to portfolio | ||
| ALIGNMENT HEALTHCARE | 8,060 | 0,00 % | Alignment Healthcare USA, LLC: Alignment Health Adds New Medicare Advantage Plan in Pima County, Increasing Access and Choice for Arizona Seniors | ||
| PRIVIA HEALTH GROUP | 22,410 | 0,00 % | Privia Health Group, Inc.: Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors | ARLINGTON, Va., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Opella Ernest, M.D. to its Board of Directors, effective September 1, 2026.... ► Artikel lesen | |
| HEARTFLOW | 56,74 | +0,05 % | Piper Sandler raises HeartFlow stock price target on competitive moat | ||
| CARL ZEISS MEDITEC | 35,540 | +1,25 % | 12 Prozent bessere Testleistung: Wie ZEISS das Zusammenspiel von Brillenglas und Gehirn untersucht | ||
| BILLIONTOONE | 107,65 | 0,00 % | BillionToOne, Inc.: BillionToOne's Tissue-Free Northstar Response Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds | MENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen | |
| CONCENTRA GROUP | 39,290 | +0,03 % | Stephens initiates Concentra stock with overweight on health model | ||
| LIFESTANCE HEALTH GROUP | 12,940 | +0,08 % | LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| PACS GROUP | 47,660 | +0,06 % | Omega Healthcare transitions 32 Florida facilities to PACS Group | ||
| GERRESHEIMER | 31,340 | -2,06 % | Gerresheimer-Aktie: Trotz der deutlichen Kurserholung noch einsteigen? | Die Gerresheimer-Aktie entwickelt sich seit dem Kurseinbruch im Februar sehr erfreulich. Notierte sie damals noch bei etwa 16 €, steht sie am Montag aktuell bei rund 30,10 €. Damit hat sich der Kurs... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 13,390 | 0,00 % | Biotech Stocks At 52-Week Highs - Park Dental Partners +10%, Aveanna Healthcare +24%, Candel Therapeutics +10% on Q2 Reports, Labcorp Holdings, Hemab Therapeutics | LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park... ► Artikel lesen |
20/20 BIOLABS INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,237 Euro und damit +0,77 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu 20/20 BIOLABS INC finden Sie auf Wallstreet Online.